These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38392960)

  • 1. Effectiveness of Switching CGRP Monoclonal Antibodies in Non-Responder Patients in the UAE: A Retrospective Study.
    Suliman R; Santos V; Al Qaisi I; Aldaher B; Al Fardan A; Al Barrawy H; Bader Y; Supena JL; Alejandro K; Alsaadi T
    Neurol Int; 2024 Feb; 16(1):274-288. PubMed ID: 38392960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study.
    Overeem LH; Peikert A; Hofacker MD; Kamm K; Ruscheweyh R; Gendolla A; Raffaelli B; Reuter U; Neeb L
    Cephalalgia; 2022 Apr; 42(4-5):291-301. PubMed ID: 34644203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study.
    Overeem LH; Lange KS; Fitzek MP; Siebert A; Steinicke M; Triller P; Hong JB; Reuter U; Raffaelli B
    Front Neurol; 2023; 14():1154420. PubMed ID: 37034092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Outcome After Switching From Galcanezumab to Fremanezumab in Patients With Migraine.
    Youn MS; Kim N; Lee MJ; Kim M
    J Clin Neurol; 2024 May; 20(3):300-305. PubMed ID: 38713076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching anti-CGRP monoclonal antibodies in chronic migraine: real-world observations of erenumab, fremanezumab and galcanezumab.
    Talbot J; Stuckey R; Wood N; Gordon A; Crossingham G; Weatherby S
    Eur J Hosp Pharm; 2024 Jan; ():. PubMed ID: 38182276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study.
    Charleston L; Talon B; Sullivan C; Anderson C; Kymes S; Regnier SA; Soni-Brahmbhatt S; Nahas SJ
    J Headache Pain; 2023 Aug; 24(1):101. PubMed ID: 37532991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway.
    Waliszewska-Prosół M; Martelletti P
    Dent Med Probl; 2024; 61(1):9-11. PubMed ID: 38284301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
    Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
    Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine.
    Mechtler L; Saikali N; McVige J; Hughes O; Traut A; Adams AM
    Front Neurol; 2021; 12():788159. PubMed ID: 35069416
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study.
    Alex A; Vaughn C; Rayhill M
    Headache; 2020 Nov; 60(10):2454-2462. PubMed ID: 32969035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.
    Schiano di Cola F; Bolchini M; Ceccardi G; Caratozzolo S; Liberini P; Rao R; Padovani A
    Eur J Neurol; 2023 Jun; 30(6):1764-1773. PubMed ID: 36856538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study.
    Varnado OJ; Brady BL; Zagar AJ; Robles YP; Hoyt M
    Patient Prefer Adherence; 2024; 18():69-88. PubMed ID: 38223442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study.
    Alsaadi T; Suliman R; Santos V; Al Qaisi I; Carmina P; Aldaher B; Haddad S; Bader Y
    Neurol Ther; 2024 Apr; 13(2):465-473. PubMed ID: 38361080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
    Saccà F; Braca S; Sansone M; Miele A; Stornaiuolo A; De Simone R; Russo CV
    Headache; 2023 Jun; 63(6):788-794. PubMed ID: 37254581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine.
    Iannone LF; Fattori D; Marangoni M; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
    CNS Drugs; 2023 Feb; 37(2):189-202. PubMed ID: 36656298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
    Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study.
    Varnado OJ; Manjelievskaia J; Ye W; Perry A; Schuh K; Wenzel R
    Patient Prefer Adherence; 2022; 16():821-839. PubMed ID: 35378732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
    Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
    CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in CGRP Monoclonal Antibodies as Migraine Therapy: A Narrative Review.
    Aditya S; Rattan A
    Saudi J Med Med Sci; 2023; 11(1):11-18. PubMed ID: 36909005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study.
    Straube A; Broessner G; Gaul C; Hamann X; Hipp J; Kraya T; Neeb L
    J Headache Pain; 2023 May; 24(1):59. PubMed ID: 37221478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.